RAD-140 is under clinical development by Ellipses Pharma and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RAD-140’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RAD-140 is under development for the treatment of metastatic breast cancer. The drug candidate is administered through oral route in the form of capsule. RAD-140 is a nonsteroidal selective androgen receptor modular (SARM). The drug candidate is developed based on the selective androgen receptor modulator discovery program.
It was also under development for age-related muscle loss, frailty, weight loss associated with cancer cachexia, osteoporosis and neurodegenerative diseases including Alzheimer's disease.
Ellipses Pharma overview
Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company has developed a technology platform to access best oncology drug assets for further investigation, analysis and clinical development. Ellipses Pharma provides a permanent source of capital for the development of cancer assets and conducts multiple oncology clinical trials in parallel supported by Scientific Affairs Group. The company is building relationships with research institutions, charitable bodies, pharmaceutical, biotechnology companies, and outsourced development providers for delivering more treatment options in oncology. Ellipses Pharma is headquartered in London, England, the UK.
For a complete picture of RAD-140’s drug-specific PTSR and LoA scores, buy the report here.